<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787396</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL011</org_study_id>
    <nct_id>NCT01787396</nct_id>
  </id_info>
  <brief_title>Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d</brief_title>
  <official_title>A Multicenter, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d Compared With Either Monotherapy in Treatment naïve Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy and safety of initial combination therapy&#xD;
      with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in treatment&#xD;
      naïve patients with type 2 diabetes, In other words, to proof superiority of initial&#xD;
      combination therapy with Gemigliptin and Metformin than each monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>24weeks</time_frame>
    <description>Evaluation variables at week 24 to baseline(Visit 2(randomization), week 0)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">433</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg + Metformin Once daily with dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 50mg</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(Metformin)</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(Gemigliptin)</intervention_name>
    <arm_group_label>Arm3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with type 2 diabetes mellitus&#xD;
&#xD;
          2. Adults over 20 of age&#xD;
&#xD;
          3. Patients with hemoglobin A1c (HbA1c) over 7.5% at Visit1(screening) and no previous&#xD;
             antidiabetic drugs before Visit 1(screening) or patients with hemoglobin A1c (HbA1c)&#xD;
             between 7%~10.5%, Patients treated with metformin monotherapy before Visit&#xD;
             1(screening).&#xD;
&#xD;
             Patients with no previous antidiabetic drugs&#xD;
&#xD;
          4. Patients with hemoglobin A1c (HbA1c) between 7.5%~11% at Visit 2(randomization)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with type 1 diabetes mellitus Diabetic ketoacidosis or Hyperosmolar&#xD;
             non-ketotic coma.&#xD;
&#xD;
          2. Patients with gestational diabetes, or secondary diabetes&#xD;
&#xD;
          3. Patients with New York Heart Association (NYHA) class III-IV congestive heart failure&#xD;
             or patients with arrhythmia requiring treatment&#xD;
&#xD;
          4. Patients with dysfunctional thyroid gland (with abnormal level of TSH)&#xD;
&#xD;
          5. Patients with active bladder cancer.&#xD;
&#xD;
          6. Tests which need to be given radiation iodide dye by intravenous.(ex, intravenous&#xD;
             urography, intravenous cholangiography, angiography, CT with dye)&#xD;
&#xD;
          7. Severe infection, pre or post operation.(Simple surgery which does not have&#xD;
             restriction of food and fluid), severe trauma patient.&#xD;
&#xD;
          8. Patients with pituitary insufficiency or adrenal dysfunction.&#xD;
&#xD;
          9. Patients with pulmonary infarction, severe pulmonary dysfunction, hypoxemia.&#xD;
&#xD;
         10. Patients with gastrointestinal disorders(ex. Dehydration, Diarrhea, Vomiting)&#xD;
&#xD;
         11. Female patients who is gravida or in lactiferous phase or confirmed pregnancy by serum&#xD;
             or urine.&#xD;
&#xD;
         12. Patients with body mass index (BMI) below 20 kg/m2 or exceeding 40 kg/m2&#xD;
&#xD;
         13. Male patients with Serum Creatinine level over 1.5mg/dl, Female patients with serum&#xD;
             creatinine over 1.4mg/dl.&#xD;
&#xD;
         14. Patients with alanine aminotransferase (ALT), aspartate aminotransferase (AST),&#xD;
             exceeding 2.5 times or bilirubin exceeding 1.5 times of the upper limit of the normal&#xD;
             range&#xD;
&#xD;
         15. Patients who were taking or needed to take any drugs that may affect the control of&#xD;
             blood glucose significantly (ex. glucocorticoids)&#xD;
&#xD;
         16. Patients taking thyroid hormone, warfarin, dicoumarin or digoxin.&#xD;
&#xD;
         17. Patients taking CYP3A4 inducers.(ex, Rifampicin(Rifampin), Dexametha-sone, Phenytoin,&#xD;
             Carbamazepine, Rifabutin, Phenobarbital)&#xD;
&#xD;
         18. Patients taking Furocemide, Nifedipine, Cimetidine&#xD;
&#xD;
         19. Patients who were treated with Anti-obesity drugs in the last 12 weeks prior to Visit&#xD;
             1(screening)&#xD;
&#xD;
         20. Patients who were treated with insulin or glucagon-like peptide-1 (GLP-1) analogue or&#xD;
             in the last 6 months prior to Visit 1.&#xD;
&#xD;
         21. Patients who had experienced myocardial infarction, unstable angina or prior history&#xD;
             of coronary artery bypass surgery within 6 months prior to Visit1(screening), or&#xD;
             patients with arrhythmia requiring treatment&#xD;
&#xD;
         22. Patients with history of addiction to alcohol or drugs within 1year prior to Visit&#xD;
             1(screening).&#xD;
&#xD;
         23. Patients with history of Diabetic ketoacidosis or Hyperosmolar non-ketotic coma.&#xD;
&#xD;
         24. Patients with history of hypersensitivity to gemiglpitin or&#xD;
             Dipeptidyl-peptidase4(DPP4) inhibitors.&#xD;
&#xD;
         25. Patients with history of hypersensitivity to metformin or biguanides.&#xD;
&#xD;
         26. Patients with history of hypersensitivity to Pioglitazone HCl or Thiazolidinediones&#xD;
&#xD;
         27. Patients who participated in other clinical trial within 3 months prior to&#xD;
             Visit1(screening).&#xD;
&#xD;
         28. Patients with other reasons who the investigator decided not to be eligible for the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LG Life Sciences</name>
      <address>
        <city>Seoul</city>
        <zip>110-062</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

